Alba P, Gómez-Puerta J A, Goycochea-Robles M V, Amigo M C
Hospital Córdoba, Cátedra de Medicina I UHMI n 3, Universidad Nacional de Córdoba, Libertad No. 2051, Córdoba, 5000, Argentina.
Grupo de Inmunología Celular e Inmunogenética (GICIG), Universidad de Antioquia, Calle 67 No. 53-108, Medellín, Colombia.
Curr Rheumatol Rep. 2016 Feb;18(2):7. doi: 10.1007/s11926-015-0556-6.
Antiphospholipid syndrome (APS) affects young patients in the most productive years of their life, and the consequences of organic or tissue damage involve a decrease in health-related quality of life (HRQoL). While acute disease manifestations of APS are well known, information on the long-term prognosis and damage in affected patients is still very limited. Systemic lupus erythematosus (SLE) patients would be expected to experience long-term complications and even die as a consequence of APS. Organ damage in APS has been evaluated using different methods and definitions, including the SLICC/ACR Damage Index (SDI), which tend to underestimate aPL-related damage. A new damage index in APS has been proposed (DIAPS), and it seems to be more accurate than SDI. Given the implications for morbidity and mortality, it is imperative to assess accurately aPL-related damage and HRQoL in patients with APS.
抗磷脂综合征（APS）在患者生命中最具生产力的阶段影响着年轻患者，器官或组织损伤的后果会导致健康相关生活质量（HRQoL）下降。虽然APS的急性疾病表现广为人知，但关于受影响患者的长期预后和损伤的信息仍然非常有限。系统性红斑狼疮（SLE）患者预计会因APS而出现长期并发症甚至死亡。APS中的器官损伤已通过不同的方法和定义进行评估，包括系统性红斑狼疮国际协作临床/美国风湿病学会损伤指数（SDI），该指数往往会低估与抗磷脂抗体（aPL）相关的损伤。已提出一种新的APS损伤指数（DIAPS），它似乎比SDI更准确。鉴于其对发病率和死亡率的影响，准确评估APS患者中与aPL相关的损伤和HRQoL至关重要。
